{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fang Y"],"funding":["National Natural Science Foundation of China"],"pagination":["423"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10631002"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>Treatment options beyond the first-line setting for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are limited. The role of the multitarget tyrosine kinase inhibitor anlotinib in RM-NPC is unclear.<h4>Methods</h4>In this prospective, single-arm, phase 2 trial, patients with histologically confirmed RM-NPC and failure of at least two lines of prior systemic treatments were eligible. Anlotinib was given at 12 mg once daily on days 1-14 every 3 weeks until disease progression or intolerable toxicities. The primary end point was disease control rate, defined as the percentage of patients achieving complete response, partial response, or stable disease by RECIST criteria.<h4>Results</h4>From April 2019 to March 2021, 39 patients were enrolled and received a median "],"journal":["BMC medicine"],"pubmed_title":["Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial."],"pmcid":["PMC10631002"],"funding_grant_id":["81672686"],"pubmed_authors":["Fang Y","Xia Y","Cai Q","Tang L","Tian X","Su N","Cao Y","Liu P","Zou Q"],"additional_accession":[]},"is_claimable":false,"name":"Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.","description":"<h4>Background</h4>Treatment options beyond the first-line setting for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are limited. The role of the multitarget tyrosine kinase inhibitor anlotinib in RM-NPC is unclear.<h4>Methods</h4>In this prospective, single-arm, phase 2 trial, patients with histologically confirmed RM-NPC and failure of at least two lines of prior systemic treatments were eligible. Anlotinib was given at 12 mg once daily on days 1-14 every 3 weeks until disease progression or intolerable toxicities. The primary end point was disease control rate, defined as the percentage of patients achieving complete response, partial response, or stable disease by RECIST criteria.<h4>Results</h4>From April 2019 to March 2021, 39 patients were enrolled and received a median ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-05-29T05:45:21.854Z","creation":"2025-04-06T14:46:19.942Z"},"accession":"S-EPMC10631002","cross_references":{"pubmed":["37936166"],"doi":["10.1186/s12916-023-03140-x"]}}